Latest News and Press Releases
Want to stay updated on the latest news?
-
Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA
-
BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA
-
The phase 3 study of toripalimab's subcutaneous injection (JS001sc) has met primary endpoints
-
FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC
-
JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study
-
Junshi Biosciences announced its 2025 interim financial results and provided corporate updates.
-
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
-
SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
-
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Toripalimab was approved by the NMPA as the first-line treatment for unresectable or metastatic melanoma, the 12th indication in the Chinese mainland.
-
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to...